导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -16.56% | 4186/4773 |
| 近一周 | -3.16% | 4600/5465 |
| 近一月 | -5.11% | 3613/5421 |
| 近一季 | -0.77% | 1128/5231 |
| 近半年 | -14.60% | 4001/4920 |
| 近一年 | -23.45% | 4034/4394 |
| 近两年 | -3.89% | 2920/2954 |
| 近三年 | -34.12% | 2232/2253 |
| 成立以来 | 214.49% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.34% 3813/4961 |
-14.75% 4603/5312 |
- - |
- - |
| 2025 | -8.22% 3387/4813 |
-1.70% 2746/3635 |
-5.01% 3527/4076 |
3.63% 3731/4524 |
-5.16% 3519/4813 |
| 2024 | -4.19% 2233/3463 |
0.19% 1025/2808 |
-11.94% 2575/3014 |
17.54% 1167/3129 |
-7.62% 2782/3463 |
| 2023 | -18.68% 1822/2656 |
3.60% 1161/2280 |
-13.13% 2199/2385 |
-1.45% 521/2515 |
-8.32% 2277/2655 |
| 2022 | -14.31% 363/2207 |
-20.49% 1550/1919 |
20.34% 57/2016 |
-12.23% 678/2113 |
2.04% 1058/2208 |
| 2021 | -6.65% 1016/1822 |
-7.92% 1070/1255 |
7.77% 668/1330 |
-11.17% 1257/1466 |
5.90% 257/1822 |
| 2020 | 88.37% 26/1250 |
-2.87% 277/1028 |
26.74% 139/1067 |
22.48% 33/1164 |
24.93% 30/1184 |
| 2019 | 67.34% 35/1092 |
40.19% 54/754 |
12.93% 2/804 |
1.93% 342/850 |
3.70% 831/918 |
| 2018 | -19.13% 156/834 |
- - |
- - |
- - |
-16.94% 644/691 |
| 2017 | 57.90% 5/714 |
- - |
- - |
- - |
- - |
| 2016 | 5.85% 15/605 |
- - |
- - |
- - |
- - |
| 2015 | 19.90% 118/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 国泰国证食品饮料行业(LOF)A VS. 长安沪深300非周期A(740101) |